Nexium brings benefit-risk into UK GSL bid

4 July 2014 - Deborah Wilkes

Archived

Pfizer Consumer Healthcare wants to have Nexium Control (esomeprazole) classified as a general-sale list (GSL) medicine in the UK, following its authorisation as a non-prescription medicine through the European Union's centralised procedure. The application includes a detailed benefit-risk analysis based on the Brass et al model supported by the World Self-Medication Industry (WSMI).

Click tags below for more information on topics:

MHRA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: